EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Progressive Amyloid‐Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier

Elisabeth Stögmann, Lukas Haider, Joel Leinkauf, Thomas Nakuz, Helena Untersteiner, Clemens Farr, Sara Silvaieh, Tandis Parvizi, Raphael Wurm, Gregor Kasprian, Thomas Berger, Ellen Gelpi, Evelyn Berger Sieczkowski

European Journal of Neurology · 2026-10 · 33 (10)

DOI: 10.1111/ene.70779 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Amyloid‐related imaging abnormalities (ARIA) are the most relevant adverse events associated with anti‐amyloid therapies in Alzheimer's disease. Methods We report a case of progressive ARIA after discontinuation of lecanemab in a patient with early‐onset Alzheimer's disease carrying the rare APOE ε2/ε4 genotype. Results After two infusions, mild ARIA‐edema (ARIA‐E) and ARIA‐hemorrhage (ARIA‐H) were detected on routine MRI, prompting treatment interruption. Despite partial radiologic regression, follow‐up MRI 8 weeks after discontinuation demonstrated marked progression with multifocal ARIA‐H displaying as superficial siderosis, while the patient remained clinically asymptomatic. Corticosteroid treatment was initiated and lecanemab permanently discontinued. Conclusion This case highlights that severe ARIA may progress beyond active treatment exposure and emphasizes the importance of continued MRI surveillance even after therapy cessation. Furthermore, the APOE ε2/ε4 genotype may represent a distinct risk factor for cerebral amyloid angiopathy‐related vascular fragility and hemorrhagic ARIA.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →